Case Report
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 6, 2019; 7(13): 1711-1716
Published online Jul 6, 2019. doi: 10.12998/wjcc.v7.i13.1711
Primary hepatoid adenocarcinoma of the lung in Yungui Plateau, China: A case report
Yun-Fei Shi, Jia-Gui Lu, Qing-Mei Yang, Jin Duan, You-Ming Lei, Wei Zhao, Yin-Qiang Liu
Yun-Fei Shi, Jia-Gui Lu, Qing-Mei Yang, Jin Duan, You-Ming Lei, Wei Zhao, Yin-Qiang Liu, Department of Thoracic Surgery in the Elderly, the First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan Province, China
Author contributions: Shi YF, Lu JG, Yang QM, Duan J, Lei YM, Zhao W and Liu YQ were involved in diagnostic flow and patient follow-up; Liu YQ contributed to interpretation of published data and drafting the manuscript; All the authors read and gave their final approval of the version to be published.
Supported by the Yunnan Health Science and Technology Plan Project Task Book, No. 2017NS020; Yunnan Provincial Health and Family Planning Commission Reserve Talent Project, No. H-2017013; Yunnan Provincial Science and Technology Project, No. 2017FE467(-142); 2018 CSCO-Qilu Tumor Project, No. Y-Q201802-011; the Educational Reform Project of Kunming Medical University, No. 2018-JY-Y-046.
Informed consent statement: Written informed consent was obtained from the patient for the publication of this case report.
Conflict-of-interest statement: The authors declare no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Yin-Qiang Liu, MD, Doctor, Surgeon, Department of Thoracic Surgery in the Elderly, the First Affiliated Hospital of Kunming Medical University, No. 295 Xichang Road, Kunming 650032, Yunnan Province, China. 823039079@qq.com
Telephone: +86-0871-65324888 Fax: +86-0871-65324888
Received: February 17, 2019
Peer-review started: February 18, 2019
First decision: March 14, 2019
Revised: March 29, 2019
Accepted: May 2, 2019
Article in press: May 3, 2019
Published online: July 6, 2019
Processing time: 138 Days and 22.5 Hours
Abstract
BACKGROUND

Hepatoid adenocarcinoma (HAC) occurs in extrahepatic organs such as the gastrointestinal tract, testes, ovaries, lungs, mediastinum and pancreas, and frequently produces α-fetoprotein (AFP). HAC of the lung (HAL) is rare, characterized by difficult treatment and poor prognosis. There are no reports of HAL in Yunnan-Guizhou Plateau, China.

CASE SUMMARY

A 60-year-old male patient was clinically diagnosed with HAL pT3N0M0, stage IIB. Chest computed tomography revealed a 7.5 cm × 7.2 cm soft tissue mass located in the right lung upper lobe and the adjacent superior mediastinum. Right upper lobectomy was performed. The diagnosis of HAL was confirmed by pathological examination, and the patient received paclitaxel and carboplatin as adjuvant chemotherapy after surgery.

CONCLUSION

Clinical manifestations, pathological features, imaging findings, auxiliary examination, and treatment planning of HAL are presented to help clinicians improve their diagnosis and treatment.

Keywords: Hepatic adenocarcinoma; Lung cancer; Immunohistochemistry; α-Fetoprotein; Case report

Core tip: We present a patient with primary hepatoid adenocarcinoma of the lung (HAL) in Yungui Plateau, China. HAL is a rare tumor involving difficult treatment and poor prognosis. We discussed the clinical manifestations, pathological features, imaging findings, auxiliary examination performance and treatment planning of HAL in order to help clinicians improve their diagnosis and treatment.